Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies

Tatiana Orme
University College London

Nigel J Cairns
Washington University School of Medicine in St. Louis

John C Morris
Washington University School of Medicine in St. Louis

et al

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Please let us know how this document benefits you.

Recommended Citation
Orme, Tatiana; Cairns, Nigel J; Morris, John C; and et al, "Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies." Acta Neuropathologica Communications. 8, 1. 5 (2020).
https://digitalcommons.wustl.edu/open_access_pubs/9277

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies


Abstract

Dementia with Lewy bodies (DBL) is a clinically heterogeneous disorder with a substantial burden on healthcare. Despite this, the genetic basis of the disorder is not well defined and its boundaries with other neurodegenerative diseases are unclear. Here, we performed whole exome sequencing of a cohort of 1118 Caucasian DLB patients, and focused on genes causative of monogenic neurodegenerative diseases. We analyzed variants in 60 genes implicated in DLB, Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia, and atypical parkinsonian or dementia disorders, in order to determine their frequency in DLB. We focused on variants that have previously been reported as pathogenic, and also describe variants reported as pathogenic which remain of unknown clinical significance, as well as variants associated with strong risk. Rare missense variants of unknown significance were found in APP, CHCHD2, DCTN1, GRN, MAPT, NOTCH3, SQSTM1, TBK1 and TIA1. Additionally, we identified a pathogenic GRN p.Arg493* mutation, potentially adding to the diversity of phenotypes associated with this mutation. The rarity of previously reported pathogenic mutations in this cohort suggests that the genetic overlap of other neurodegenerative diseases with DLB is not substantial. Since it is now clear that genetics plays a role in DLB, these data suggest that other genetic loci play a role in this disease.

Introduction

Dementia with Lewy bodies (DBL) is a neurodegenerative disease that shares clinical and pathological features with both Parkinson’s disease (PD) and Alzheimer’s disease (AD). A disease most often occurring in the elderly demographic, it exhibits a varied clinical presentation that can include dementia, parkinsonism, visual hallucinations, REM sleep behavior disorder, fluctuations in attention and alertness, as well as autonomic and psychiatric dysfunction [49], all described as clinical features of underlying synucleinopathy. Similar to PD, the pathological hallmark of DLB is accumulation of alpha-synuclein in Lewy bodies (LBs) and Lewy neurites, leading to consideration of these conditions as different ends of the same clinico-pathological spectrum. Lewy-related pathology in DBL can be found not only in the brainstem, but also widespread in limbic and/or neocortical regions [47]. Alzheimer pathology in the form of
amyloid plaques and tau neurofibrillary tangles are frequently found at autopsy [17].

At present, knowledge of the genetic etiology of DLB is limited. Families with the disorder are rare, and SNCA multiplications and point mutations have been shown to cause disease in multiplex families of mixed Parkinson’s disease and dementia [31, 63, 77]. Variants in PRNP [38] and SNCA [55] have been reported in DLB, but their pathogenicity has been questioned due to lack of replication, lack of segregation [55], or presence in healthy controls [8]. DLB shares risk loci that are associated with AD or PD, and we have recently shown the genetic correlation between DLB and PD, and DLB and AD, is approximately equal when disregarding APOE [26]. The APOE ε4 allele strongly predisposes to the development of the disorder [13, 57, 64, 69], as do certain variants in the GBA gene [53]. A non-synonymous variant in PLCG2 has been proposed to confer protection from AD [62], and more recently, DLB and frontotemporal dementia (FTD) [71]. An association at the SNCA locus was identified, which, interestingly, shows a differential association profile in DLB than that seen in PD [13]. Furthermore, the first genome-wide association study (GWAS) was recently published, analyzing the genotyping data from 1743 DLB patients, a proportion of whom (745 samples) are also included in this study. In a two-stage study design, the associations at APOE, GBA and SNCA were replicated, and novel loci reached suggestive levels of association [27]. It has been proposed that rare variants in AD and PD causing genes may also play a role in sporadic DLB. However, these studies have been small, with sample sizes of approximately 100 cases [36, 37, 51]; it is thus uncertain whether these findings are merely coincidental.

We performed exome sequencing of over 1000 DLB patients to investigate the role of genetic variants in not only AD and PD genes, but additionally in a collection of approximately 40 disease genes established as causative of neurodegenerative diseases. The genetic variants studied were those previously implicated in FTD with or without amyotrophic lateral sclerosis (ALS); atypical parkinsonian disorders; and disorders with dementia as a presenting feature.

As DLB is a heterogeneous disorder, and has overlapping features with other diseases, accurate diagnosis relies on the combination of clinical and pathological assessments. To mitigate this issue as much as possible, the DLB patients included in this study had a neuropathological diagnosis of DLB.

**Methods**

**Cohort studied**

We studied 1118 patients neuropathologically diagnosed according to the 2005 McKeith diagnosis guidelines [49], as meeting the criteria for ‘intermediate’ or ‘high’ likelihood DLB and self-reported as Caucasian. The mean age at death in the cohort was 78.8 (±8.4) years and the male to female ratio was 1.5.

**Exome sequencing and data analysis**

DNA was extracted from the cerebellum or frontal cortex using standard methods [75]. Exome sequencing was performed using Illumina’s Nextera Rapid Expanded Exome capture (62 Mb), or Agilent SureSelect Exome Capture Kit (v4) and sequenced on Illumina’s HiSeq2500 using 100 bp paired-end reads. On target average coverage of at least 30x was obtained for all included samples. Data analysis was performed according to standard GATK (v3) best practices [50] using a single informatics pipeline and performing joint variant calling of single nucleotide variants (SNVs) and short insertions and deletions (indels) across all samples. In brief, sequencing reads were aligned to the human reference genome (GRCh37/hg19) using bwa-mem (v0.7.12), duplicate reads were flagged using samblaster (v0.1.21), and realignment around indels and base quality scores were recalibrated using GATK. Variant recalibration was performed using GATK’s variant quality score recalibration (VQSR) [21, 70]. Variants that did not meet the VQSR threshold of 99.9 were excluded. Individual genotypes with a phred-scaled quality score below 20 and with coverage below 8 were set to missing. Variants were included only if they had a high call rate in both capture kits (genotyped in ≥90% of samples). Annotation of variants was performed with snpEff (v4.2) [15] and dbNSFP v2.9 [44] using GRCh37/hg19 as reference.

**Sample quality control (QC)**

Sample quality control metrics were generated using PLINK 1.9 [58]. Population structure was analysed using principal component analysis, and samples that did not cluster with the European population of the 1000 Genomes dataset were removed from analysis. Concordance between reported and genotype sex was performed for each sample to remove those with a discordant sex assignment. Samples with inconsistent heterozygosity rates, or that were shown to be related or duplicated were excluded. Due to linkage disequilibrium, population structure and genotyping error, we removed an individual from a pair of samples using a proportion of identity by descent threshold of ≥0.1875 [3]. After QC measures, we analyzed variants from 1004 DLB patients. The locations from which the DLB samples were sourced can be found in Additional file 1: Table S1.

**Neurodegenerative disease genes**

Fifty-seven genes were selected based on their role in monogenic forms of neurodegenerative diseases including AD, PD, FTD and related Mendelian disorders featuring parkinsonism or dementia. Due to its relevance to DLB, we also report on variants in GBA and APOE, as well as
the PLCG2 p.Pro522Arg variant. A full list of the studied genes can be found in Additional file 2: Table S2.

We focused on variants that were amino acid changing; or that fell in splice donor/acceptor sites; in splice regions, or in 5′ or 3′ untranslated regions.

A literature search was conducted for each disease-causing gene studied in order to identify previously reported pathogenic mutations. This included primary literature reports; supplementary information; the Human Gene Mutation Database [66]; the Online Mendelian Inheritance in Man website [2]; the AD & FTD, and PD mutation databases [20]; and Clinvar [39]. Population variant frequency was determined using gnomAD (v2.1), a genomic database consisting of variants from 125,748 exomes and 15,708 genomes [34, 41].

The maximum frequency that a known pathogenic variant occurs in a large cohort of a disease of interest allows for an estimation of the maximum tolerated frequency of a pathogenic variant for that disease [74]. As the genetics of DLB is yet to be fully delineated, we used Alzheimer’s disease to estimate a maximum tolerated allele count for a pathogenic variant to occur in the gnomAD database, implemented using the alleleFrequencyApp http://cardiob.org/allelefrequencypapp/ [74]. This was used as a conservative approximation of maximum tolerated variant frequencies for pathogenic mutations in the general population for a disease such as AD.

Reported variants were also analysed for their frequency in 432 control individuals from the Healthy Exomes (HEX) dataset, who died aged 60 or over, without any disease-associated neuropathology [29, 28].

**APOE genotyping**

Given the difficulty in sequencing the APOE locus, the APOE haplotype was confirmed in samples where DNA was available (n = 758 samples). APOE haplotype genotyping was conducted using enzyme restriction, as previously described [29].

**Sanger sequencing**

Candidate variants were confirmed by Sanger sequencing when DNA was available. DNA was amplified by polymerase chain reaction using Roche FastStart PCR Master Mix (Roche Diagnostics Corp) and sequenced with Applied Biosystems BigDye terminator version 3.1 sequencing chemistry in an ABI3730XL genetic analyzer as per manufacturer’s instructions (Applied Biosystems). Primers are available upon request. The sequences were analysed using Sequencher software version 4.2 (Gene Codes).

**Results**

We performed a detailed analysis of the genetic variability of 57 genes shown previously to cause neurodegenerative diseases in over 1000 DLB cases. Furthermore, we also report on GBA and APOE, well established risk genes for DLB, as well as the recently reported protective PLCG2 p.Pro522Arg variant.

We identified a pathogenic nonsense mutation in GRN, p.Arg493* (ENST00000053867), in one patient. This variant was confirmed by Sanger sequencing. In addition, we identified previously reported mutations that, due to their low frequency in the general population, have uncertain clinical significance (Table 1). No previously reported pathogenic homozygous variants were identified in genes that cause neurodegenerative disease with autosomal recessive inheritance. As the data was not phased, compound heterozygous variants could not be completely assessed.

**GRN p.Arg493**

The patient with the p.Arg493 GRN mutation had a medical history that included a stroke, and previous surgical evacuation of a subdural haematoma, as well as a family history of AD in a parent and a sibling, with onset in the seventh decade. The presenting symptom was episodes of confusion, and a CT scan showed moderate cerebral and cerebellar atrophy with a lacunar infarct in the left external capsule. Subsequent symptoms included memory loss, disorientation, altered gait, stooped posture, right-sided rigidity and visual hallucinations. Impaired smooth pursuit, left hemiparesis, left spasticity, right-sided rigidity, and a slight parkinsonian tremor of the left hand were also reported. The patient was severely demented and scored 3/30 on the Mini Mental State Examination (MMSE) in an assessment conducted at 83 years, approximately 2 years before death.

Macroscopically, the right convexity of the brain showed very marked asymmetrical atrophy of the frontal, temporal and parietal lobes, with knife-edge atrophy at the frontal and temporal poles, and mild atrophy of the right occipital lobe. There were no focal lesions. Pathological examination with immunohistochemical staining for alpha-synuclein protein showed a single LB in the substantia nigra; very infrequent Lewy bodies in multiple cortical areas; sparse LBs in the anterior cingulate, entorhinal and transentorhinal cortices; and no LBs in the amygdala. Thioflavin S methods showed frequent diffuse amyloid plaques in neocortical areas. Very infrequent neurofibrillary tangles were present in the nucleus basalis of Meynert, hypothalamus and entorhinal cortex, and were absent from all neocortical areas examined. Immunohistochemical staining for abnormal tau protein identified frequent dot-like features and diffusely stained neurons in the entorhinal cortex, transentorhinal cortex, CA1 and subiculum of the hippocampus and the parahippocampal gyrus. There were sparse argyrophilic grains in the amygdala, entorhinal cortex and area CA1 of the subiculum. Immunohistochemical staining for ubiquitin showed moderate densities of short neuropil threads and dots, as well as sparse to moderate densities of small cytoplasmic inclusions in layer II of
Table 1: Heterozygous variants of uncertain clinical significance that were found in the DLB case cohort. The variant in *DCTN1* was found in two DLB cases. All other variants were seen in single DLB cases. Variants are included in Table 1 if they were previously reported, but not fully established as pathogenic, and if they were present five times or less in the European (non-Finnish) population in gnomAD.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Transcript</th>
<th>Variant</th>
<th>Number of DLB patients</th>
<th>GnomAD MAF (all populations)</th>
<th>GnomAD NFE AC (Total NFE AN)</th>
<th>Previously reported</th>
<th>Additional information</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>APP</td>
<td>ENST0000346798</td>
<td>c.2020G &gt; A p.Glu674Lys</td>
<td>1</td>
<td>0</td>
<td>Not present</td>
<td>In AD: adjacent amino acid (p.A673T) protective, or (p.A673V) causes EOAD when homozygous</td>
<td>Variant newly identified here. Adjacent amino acid plays a role in disease</td>
<td>[22, 32]</td>
</tr>
<tr>
<td>CHCHD2</td>
<td>ENST0000395422</td>
<td>c.10G &gt; A p.Gly4Arg</td>
<td>1</td>
<td>0.00002840</td>
<td>4 (128432)</td>
<td>1 LBD patient</td>
<td>–</td>
<td>[54]</td>
</tr>
<tr>
<td>DCTN1</td>
<td>ENST0000361874</td>
<td>c.2339 T &gt; C p.Ile780Thr</td>
<td>2</td>
<td>0.00003889</td>
<td>5 (129150)</td>
<td>1 patient with FALS, control</td>
<td>Low frequency in gnomAD, but also found in a control</td>
<td>[35]</td>
</tr>
<tr>
<td>GRN</td>
<td>ENST0000053867</td>
<td>c.827C &gt; T p.Ala276Val</td>
<td>1</td>
<td>0.000007075</td>
<td>1 (129048)</td>
<td>1 patient with an initial diagnosis of FTD which was changed to depression</td>
<td>Variant found in a patient included in a neurodegenerative disease cohort, but diagnosis was changed from FTD</td>
<td>[76]</td>
</tr>
<tr>
<td>MAPT</td>
<td>ENST0000344290</td>
<td>c.256G &gt; A p.Gly86Ser</td>
<td>1</td>
<td>0.00002901</td>
<td>4 (126300)</td>
<td>1 patient with clinical FTD</td>
<td>Segregation not proven</td>
<td>[65]</td>
</tr>
<tr>
<td>NOTCH3</td>
<td>ENST0000263388</td>
<td>c.1732C &gt; T, p.Arg578Cys</td>
<td>1</td>
<td>0.00003989</td>
<td>2 (113234)</td>
<td>Found in several CADASIL, but also seen in 1 control</td>
<td>Homozygous variant carrier had a mild phenotype</td>
<td>[1, 14, 33, 43, 68]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>c.1733G &gt; A, p.Arg578His</td>
<td>1</td>
<td>0.000007980</td>
<td>0 (113200)</td>
<td>p.Arg578Cys (different amino acid change) seen in CADASIL</td>
<td>Different amino acid change than previously reported; not cysteine changing</td>
<td>[14]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>c.1820G &gt; A, p.Arg607His</td>
<td>1</td>
<td>0.000004000</td>
<td>1 (112826)</td>
<td>1 CADASIL, and a different amino acid change, p.Arg607Cys seen in several CADASIL patients</td>
<td>Filtered site in gnomAD, may be false positive. Not cysteine changing</td>
<td>[1, 46, 67]</td>
</tr>
<tr>
<td>SQSTM1</td>
<td>ENST0000389805</td>
<td>c.1210A &gt; G p.Met404Val</td>
<td>1</td>
<td>0.00001591</td>
<td>3 (113732)</td>
<td>Several families with Paget's disease of bone</td>
<td>Variant shown to cause Paget's disease of bone (not FTD-ALS)</td>
<td>[23, 30]</td>
</tr>
<tr>
<td>TJK1</td>
<td>ENST0000331710</td>
<td>c.1150C &gt; T p.Arg384Thr</td>
<td>1</td>
<td>0.00002128</td>
<td>4 (128892)</td>
<td>p.Arg384Thr (different amino acid change) reported in 1 ALS</td>
<td>Different amino acid change than previously reported. Variation in the same amino acid in 2 different DLB cases in this study</td>
<td>[12]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>c.1151G &gt; A, p.Arg384Gln</td>
<td>1</td>
<td>0.00008514</td>
<td>3 (128842)</td>
<td>p.Arg384Thr (different amino acid change) reported in 1 ALS</td>
<td>Different amino acid change than previously reported. Variation in the same amino acid in 2 different DLB cases in this study</td>
<td>[12]</td>
</tr>
<tr>
<td>TIA1</td>
<td>ENST0000433529</td>
<td>c.1085C &gt; T p.Pro362Leu</td>
<td>1</td>
<td>0.00002121</td>
<td>2 (129146)</td>
<td>2 s degree relatives with FTD/ALS</td>
<td>Unreplicated report suggests this variant causes ALS/FTD</td>
<td>[45]</td>
</tr>
</tbody>
</table>

*Ref* Reference, MAF Minor Allele Frequency, gnomAD NFE Non-Finnish European, AC Allele Count, AN Allele Number, FTD/ALS Frontotemporal Dementia / Amyotrophic Lateral Sclerosis, CADASIL Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy, EOAD Early Onset Alzheimer's disease, FALS Familial Amyotrophic Lateral Sclerosis, SALS Sporadic Amyotrophic Lateral Sclerosis, LBD Lewy Body Disease, AD Alzheimer's disease, PD Parkinson's disease
frontal and temporal neocortical regions. Following the identification of the mutation, the sample was stained for TDP-43 and revealed inclusions in frontal and temporal lobes. Sections stained immunohistochemically for phosphorylated TDP-43 protein showed immunoreactive dystrophic puncta, neurites and perikaryal cytoplasmic inclusions within layer II of frontal and temporal neocortical areas, as well as the amygdala, hippocampal CA1 region, and entorhinal cortex. These features reached moderate to frequent densities in the frontal and temporal neocortex.

**Established risk factors for DLB**
No homozygous Gaucher disease causing variants were identified in GBA. Table 2 details variants found in GBA that had a call-rate of 90% or greater. Two variants, p.Glu365Lys and p.Asn409Ser were over-represented in DLB compared to the gnomAD database. Of note, 2 homozygous carriers of p.Glu365Lys were identified and a novel variant, p.Asn409del, was identified in 1 patient in the cohort.

**Potentially pathogenic variants**
We used Alzheimer’s disease genetics as a model in order to apply an approximate threshold for the tolerated occurrence of pathogenic AD mutations in gnomAD. We applied an AD prevalence of 1/79 (Alzheimer Society Dementia recurrence of pathogenic AD mutations in gnomAD. We applied an approximate threshold for the tolerated occurrence of pathogenic AD mutations in gnomAD. We applied an AD prevalence of 1/79 (Alzheimer Society Dementia report, 2014); a maximum estimated disease-causing MAF of 0.0012; and a very conservative penetrance threshold of 0.5. The maximum tolerated frequency for a pathogenic allele for AD using the allele number of a variant genotyped in the entire gnomAD European (non-Finnish) population was $1.5556 \times 10^{-0.5}$, or five alleles. This is a very conservative approximation, likely to be too high since AD is more prevalent than DLB, however since the genetic architecture of DLB still remains largely unresolved, we used AD as an approximation. In Table 1 we describe previously reported variants of unknown clinical significance that were present in 5 or less Europeans in the gnomAD database. None of these variants were detected in the control individuals from the HEX dataset. These variants were identified in APP, CHCHD2, DCTN1, GRN, MAPT, NOTCH3, SQSTM1, TBK1 and TIA1. Variants were reported in Table 1 if the evidence for pathogenicity was moderate, such as having unproven segregation with disease; eliciting a different amino acid change than was previously reported; identified in a gene that has not been replicated as causative for disease; or if the variant has also been identified in a control subject. Table 1 also shows variants not present in Europeans in gnomAD that affect the same or an adjacent amino acid as previously reported in disease. Table 3 lists variants identified in multiple DLB cases and with 5 or less alleles in gnomAD.

Variants that have previously been reported in disease, but were more frequent in the general population, thus less likely to be fully penetrant, disease-causing alleles, are reported in Additional file 3: Table S3. These include variants such as SNCB p.His50Gln, which is present in 19 Europeans in gnomAD, and whose pathogenicity has been disputed [10].

**Genes previously reported in DLB**
We investigated variants in genes that have been reported as causative of DLB - PRNP and SNCB - as well as a gene in which a variant was recently reported as protective for DLB - PLCG2.

The previously identified PRNP p.Met232Arg [38] variant was not present in our cohort, and there were no other previously reported pathogenic variants in PRNP in our data. It is therefore unlikely that PRNP mutations cause sporadic DLB in the European population.

The SNCB p.Val70Met and p.Pro123His variants reported to predispose to DLB [55] were also not found in our cohort of DLB cases, suggesting that if they play a role in DLB, they may be population specific risk factors. In our cohort, no non-synonymous variants were found in the SNCB gene, even though the entire gene was adequately covered.

A variant in PLCG2, p.Pro522Arg, has been reported to reduce the risk of DLB, AD and FTD [71]. This variant was identified in 18 DLB cases (MAF 0.0089), which is similar to the frequency found in gnomAD non-Finnish Europeans (MAF 0.0087).

**TREM2**
TREM2 is the second strongest genetic risk factor for AD, an effect largely driven by the p.R47H variant. In our data, the p.Arg47His variant, which was successfully sequenced in 667 of the 1004 samples, had a MAF 0.00299, which is similar to the frequency in NFEs in gnomAD (MAF 0.002466). The p.Arg62His variant also had a similar MAF in DLB (0.0142), compared to Europeans in the gnomAD database (0.0112). Likewise, the frequency of p.Thr96Lys and p.Leu211Pro variants was similar in DLB patients and gnomAD, (MAF 0.00991 versus 0.00101, and MAF 0.000992 versus 0.00101), respectively. No homozygous variants in TREM2 were identified.

**Discussion**
We present a comprehensive analysis of rare genetic variability in an extensive number of neurodegenerative disease-causing genes in a large cohort of patients diagnosed with DLB. We used state-of-the-art analytical approaches with well-established quality control criteria that allowed us to identify genetic variability and estimate its contribution to disease.
<table>
<thead>
<tr>
<th>Variant</th>
<th>Annotation</th>
<th>Heterozygous DLB cases</th>
<th>DLB MAF</th>
<th>MAF in-house controls (n = 432)</th>
<th>gnomAD NFE AC</th>
<th>gnomAD NFE AC, AN (number of homozygotes)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1155205518 C/G (rs1064651)</td>
<td>p.Asp448His missense variant</td>
<td>2</td>
<td>0.000991</td>
<td>0</td>
<td>0.000179, failed quality filters</td>
<td>AC = 23, AN = 128,640 (0)</td>
</tr>
<tr>
<td>1155205563 C/A (rs80356769)</td>
<td>p.Val433Leu missense variant</td>
<td>2</td>
<td>0.000991</td>
<td>0</td>
<td>0</td>
<td>AC = 0, AN = 113,740 (0)</td>
</tr>
<tr>
<td>1155205581 C/T (rs149171124)</td>
<td>p.Glu427Lys missense variant</td>
<td>2</td>
<td>0.000991</td>
<td>0</td>
<td>0.000263</td>
<td>AC = 34, AN = 129,176 (0)</td>
</tr>
<tr>
<td>1155205632 GGT/G</td>
<td>p.Asm409del</td>
<td>1</td>
<td>0.000547</td>
<td>0</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>1155205634 T/C (rs76763715)</td>
<td>p.Asm409Ser</td>
<td>19</td>
<td>0.009958</td>
<td>0.0023202</td>
<td>0.002045</td>
<td>AC = 264, AN = 129,124 (2)</td>
</tr>
<tr>
<td>1155205638 A/G (rs377143075)</td>
<td>c.1225-3 T &gt; C</td>
<td>1</td>
<td>0.000529</td>
<td>0</td>
<td>0.00093</td>
<td>AC = 12, AN = 129,160 (0)</td>
</tr>
<tr>
<td>1155206117 A/G (rs75502134)</td>
<td>p.Cys381Cys</td>
<td>1</td>
<td>0.00496</td>
<td>0</td>
<td>0.00009</td>
<td>AC = 1, AN = 113,740 (0)</td>
</tr>
<tr>
<td>1155206157 C/T (rs1064648)</td>
<td>p.Arg368His</td>
<td>1</td>
<td>0.00496</td>
<td>0</td>
<td>0.000101</td>
<td>AC = 13, AN = 129,174 (0)</td>
</tr>
<tr>
<td>1155206167 C/T (rs2230288)</td>
<td>p.Glu365Lys</td>
<td>75</td>
<td>0.039187</td>
<td>0.01042</td>
<td>0.012340</td>
<td>AC = 1594, AN = 129,170 (11)</td>
</tr>
<tr>
<td>1155206187 G/A</td>
<td>p.Pro358Leu</td>
<td>1</td>
<td>0.00496</td>
<td>0</td>
<td>0</td>
<td>NA</td>
</tr>
<tr>
<td>1155206200 C/G (rs398123526)</td>
<td>p.Asp354His</td>
<td>1</td>
<td>0.00496</td>
<td>0</td>
<td>0.00026</td>
<td>AC = 3, AN = 113,764 (0)</td>
</tr>
<tr>
<td>1155206262 T/G (rs1064652)</td>
<td>c.1000-2A &gt; C</td>
<td>1</td>
<td>0.00496</td>
<td>0</td>
<td>0.00000</td>
<td>NA</td>
</tr>
<tr>
<td>1155207965 C/T (rs409652)</td>
<td>p.Gly241Arg</td>
<td>2</td>
<td>0.00992</td>
<td>0</td>
<td>0.00035</td>
<td>AC = 4, AN = 113,766 (0)</td>
</tr>
<tr>
<td>1155208060 C/G</td>
<td>p.Arg209Pro</td>
<td>1</td>
<td>0.00496</td>
<td>0</td>
<td>0</td>
<td>NA</td>
</tr>
<tr>
<td>1155209539 G/A (rs368145008)</td>
<td>p.Leu108Leu</td>
<td>1</td>
<td>0.00520</td>
<td>0</td>
<td>0.00023</td>
<td>AC = 3, AN = 129,172 (0)</td>
</tr>
<tr>
<td>1155209737 G/A (rs1141812)</td>
<td>p.Arg83Cys</td>
<td>2</td>
<td>0.00992</td>
<td>0</td>
<td>0.00054</td>
<td>AC = 7, AN = 129,080 (0)</td>
</tr>
<tr>
<td>1155210918 T/C (rs41264927)</td>
<td>c.-15A &gt; G</td>
<td>2</td>
<td>0.00992</td>
<td>0</td>
<td>0.001641</td>
<td>AC = 212, AN = 129,174 (0)</td>
</tr>
</tbody>
</table>

All variants were found in the heterozygous state, apart from the variant in bold, p.Glu365Lys, which was found as a homozygous variant in 2 DLB cases. The frequency of these variants are also reported in 432 in-house controls who died aged 60 or over without disease neuropathology. MAF Minor Allele Frequency, gnomAD NFE Non-Finnish European, AC Allele Count, AN Allele Number
Mutations in GRN cause FTD [7, 19], and the most commonly reported pathogenic mutation in GRN is p.Arg493* [59]. The patient described here lacked prominent clinical signs of FTD, such as changes in behavior, personality, or language impairment. Severe dementia, parkinsonism and visual hallucinations were present, and led to the suggested clinical diagnosis of Alzheimer’s disease or mixed vascular dementia, with a final neuropathological diagnosis of Alzheimer’s disease, dementia with Lewy bodies and argyrophilic grain disease. Substantial phenotypic variability has been described in patients with a GRN p.Arg493* mutation. In 34 patients identified with this mutation, 25 had a diagnosis of FTD; 4 of primary progressive aphasia; 3 of corticobasal syndrome and 3 of Alzheimer’s disease. Age at onset ranged from 44 to 69, and the most common initial symptom was a change in personality or executive dysfunction (25/33 patients), with subsequent language impairment occurring in 26 of 33 patients. Fourteen out of thirty patients had parkinsonism and 10% had visual hallucinations [59]. This mutation has also been found in 4 patients with sporadic Alzheimer’s disease [24].

An overlap between FTD and DLB has been shown both clinically and neuropathologically. Several patients have been identified that simultaneously met clinical criteria for both FTD and DLB [16, 52], or that presented clinically with FTD, but at autopsy had DLB [11, 61]. Concomitant TDP-43 and alpha-synuclein pathology can be found in 27–60% of DLB cases at autopsy [4, 17, 48]. In general, GRN mutations result in disease with clinical heterogeneity [40, 72, 73], and it is possible that overlaps between DLB and FTD may be connected to variation in GRN. It is also possible that hallucinations and delusions in GRN carriers may cause a misdiagnosis of DLB [9]. An FTD case harboring the GRN p.Thr382fs mutation showed a phenotype resembling Parkinson’s disease, with fluctuations in cognition, parkinsonism and visual hallucinations [5]. Furthermore, alpha-synuclein and TDP-43 pathologies were found in a subset of brains of patients with a GRN mutation [42]. A small study in 58 DLB cases showed that together, rare variants in GRN are associated with DLB [37], although this is yet to be independently replicated. A recent study identified 9 heterogeneous FTLD cases with coexisting Lewy body pathology Braak stage ≥ IV, comprising 7% of the cohort. Two of the 9 cases had a secondary diagnosis of DLB, and a further 2 had GRN mutations [25]. Progranulin and β-amyloid have been shown to co-localize in plaques in DLB, suggesting a possible biological association between these two aggregated proteins [60]. However, there are often multiple concomitant pathologies that are identified in neurodegenerative disease, and so the observation of TDP-43 with Lewy and amyloid pathology could simply be coincidental multi-morbidity of simultaneous pathologies that coexist in the ageing brain [6]. After the identification of the GRN mutation, additional clinicopathological information was reviewed to assess this case. The histopathological findings of the p.Arg493* carrier revealed Lewy bodies; amyloid plaques; argyrophilic grains; ubiquitin positive inclusions; tau staining, and when reanalysed, TDP-43 pathology. The medical history reported the occurrence of a stroke, which was also confirmed by a CT scan, however no further clinical information was available. Taken together, these facts add to the difficulty in classifying these more complex forms of disease. Particularly in archive cases where the neuropathology assessment did not originally include staining for TDP-43.

We identified possible pathogenic variants in other genes linked to the FTD-ALS spectrum of disease. A variant in TIA1, p.Pro362Leu, suggested to be causative of ALS/FTD, was found in 1 DLB patient in the cohort. TIA1 encodes an RNA-binding protein, and this variant was reported in a pair of second degree relatives with ALS/FTD, as well as a clinically symptomatic, but non-demented relative. An increased burden of rare heterozygous TIA1 mutations in a larger ALS/FTD cohort was reported [45]. In two neuropathologically diagnosed DLB cases, we found two variants in TBI1 that affected the same amino acid: p.Arg384Trp and p.Arg384Gln. This amino acid has been found to be altered in a sporadic Sardinian ALS case (p.Arg384Thr) [12]; a variant not present in gnomAD, but whose pathogenicity is unconfirmed. It is intriguing that two DLB cases were identified with variants that affect the same amino acid.

Table 3 Variants found in more than 1 DLB case, that were present in 5 or less individuals from the gnomAD exome dataset of non-Finnish Europeans

<table>
<thead>
<tr>
<th>Gene</th>
<th>Transcript</th>
<th>Variant</th>
<th>Number of DLB cases</th>
<th>GnomAD NFE AC (Total NFE AN)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PARK2</td>
<td>ENST0000366898</td>
<td>p.Gln440Arg</td>
<td>2</td>
<td>1 (112822)</td>
</tr>
<tr>
<td>VPS13C</td>
<td>ENST0000261517</td>
<td>p.Ile288Met</td>
<td>2</td>
<td>4 (112094)</td>
</tr>
<tr>
<td>TUBA4A</td>
<td>ENST00000248437</td>
<td>p.Val181Met</td>
<td>2</td>
<td>5 (113764)</td>
</tr>
<tr>
<td>DNAJC6</td>
<td>ENST00000371069</td>
<td>p.Val632 Ala</td>
<td>2</td>
<td>0 (83222)</td>
</tr>
<tr>
<td>VPS35</td>
<td>ENST00000299138</td>
<td>p.Arg499His</td>
<td>2</td>
<td>4 (113646)</td>
</tr>
</tbody>
</table>

All variants were identified in the heterozygous state. gnomAD NFE Non-Finnish European, AC Allele Count, AN Allele Number
These variants are present in gnomAD (MAFs 0.0000213 and 0.0000851, respectively). At present, their contribution to DLB is unclear.

From the perspective of AD related genetics, we identified a variant of unknown significance in APP - p.Glu674Lys - in a DLB case, a substitution of a negatively charged amino acid to a positively charged amino acid at the 3rd residue of the β-amyloid peptide. This variant was not present in the gnomAD database, and affects an adjacent amino acid to that previously described. The p.Ala673Val was shown to cause early onset Alzheimer’s disease in the homozygous state, whereas heterozygous individuals in the family were unaffected [22]. A different amino acid change at the same position, p.Ala673Thr, has been reported in a patient without AD [56], and predicted as non pathogenic due to non segregation with disease in a family [18]. Furthermore, this variant was shown to be protective against Alzheimer’s disease in the Icelandic population, where it resulted in a reduction of beta-secretase cleavage in vitro [32].

We have also looked at strong risk modulating genes: GBA, TREM2, APOE and PLCG2. If at GBA and APOE we saw evidence of increased frequency in the previously reported variants, we did not observe such a finding at TREM2 or PLCG2, with both showing frequencies that are identical to those found in the general population.

We have also identified a number of possible pathogenic mutations in several other genes studied here (Table 1). The design of this study does not allow variant pathogenicity to be unequivocally established, and, in this way, we report these variants to allow future studies to attempt confirmation of these findings.

In summary, we provide the first large-scale characterization of rare genetic variability in the most relevant neurodegenerative disease-causing genes in DLB. Our findings suggest that mutations in genes known to cause other neurodegenerative diseases are not a common cause of DLB.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s40478-020-0879-2.

Acknowledgements
This work was supported in part by the National Institutes of Neurological Disease and Stroke and by the Alzheimer’s Society. TO was supported by a scholarship from the Lewy Body Society. We would like to thank Dr. Daniela Hansen from the Reta Lila Weston Institute at the Institute of Neurology, UCL. For the neuropathologically confirmed samples from Australia, tissues were received from the Sydney Brain Bank which is supported by Neuroscience Research Australia and the University of New South Wales. We acknowledge the Oxford Brain Bank, supported by the Medical Research Council (MRC), Bra ins for Dementia Research (BDR) (Alzheimer Society and Alzheimer Research UK), Autism UK and the NIHR Oxford Biomedical Research Centre. We would like to thank the South West Dementia Brain Bank (SWDBB) for providing brain tissue for this study. The SWDBB is part of the Brains for Dementia Research programme, jointly funded by Alzheimer’s Research UK and Alzheimer’s Society and is supported by BRACE (Bristol Research into Alzheimer’s and Care of the Elderly) and the Medical Research Council. Regarding the brain samples and/or bio samples that were obtained from The Netherlands Brain Bank, Netherlands Institute for Neuroscience, Amsterdam (open access: www.brainbank.nl); all Material has been collected from donors for or from whom a written informed consent for a brain autopsy and the use of the material and clinical information for research purposes had been obtained by the NBB. This study was also partially funded by the Canadian Consortium on Neurodegeneration in Aging (Rogaeva and St. George-Hyslop). The Nottingham Genetics Group is supported by ARUK and The Big Lottery Fund. The effort from Columbia University was supported by the Taub Institute, the Panucci Fund, the Parkinson’s Disease Foundation, and NIH grants NS506113 (L. Clark), P50AG089702 (P.I. Scott Small), P50NS038370 (P.I. R. Burke), and UL1TR000040 (P.I. H. Ginsberg). O.A.R. is supported by the Michael J. Fox Foundation, NINDS R01 NS078086. The Mayo Clinic Jacksonville is a Morris K. Udall Parkinson’s Disease Research Center of Excellence (NINDS P50 #NS072187) and is supported by The Little Family Foundation and by the Magazun Foundation Program for Lewy Body Dementia research and the Alzheimer Disease Research Center (PS0 AG016547). The Brain and Body Donation Program (TGB) has been supported by the National Institute of Neurological Disorders and Stroke (U24 NS072026 National Brain and Tissue Resource for Parkinson’s Disease and Related Disorders), the National Institute on Aging (P30 AG19610 Arizona Alzheimer’s Disease Core Center), the Arizona Department of Health Services (contract 211002, Arizona Alzheimer’s Research Center), the Arizona Biomedical Research Commission (contracts 4001, 0011, 01-001 and AG01 to the Arizona Parkinson’s Disease Consortium) and the Michael J. Fox Foundation for Parkinson’s Research. The work from the Mayo Clinic Rochester is supported by the National Institute on Aging (PS0 AG016574 and U01 AG06796). This work has received support from The Queen Square Brain Bank at the UCL Institute of Neurology, where TL is funded by an ARUK senior fellowship. Some of the tissue samples studied were provided by the MRC London Neurodegenerative Diseases Brain Bank and the Brains for Dementia Research project (funded by Alzheimer’s Society and ARUK). This research was supported in part by both the NIHR UCLH Biomedical Research Centre and the Queen Square Dementia Biomedical Research Unit. This work was supported in part by the Intramural Research Program of the National Institute on Aging, National Institutes of Health, Department of Health and Human Services; project AG000951-12. The University of Pennsylvania case collection is funded by the Penn Alzheimer’s Disease Core Center (AG10124) and the Penn Morris K. Udall Parkinson’s Disease Research Center (NS053488). The authors would like to thank the Genome Aggregation Database and the groups that provided exome and genome variant data for comparison. A full list of contributing groups can be found at https://gnomad.broadinstitute.org/. Tissue samples from UCSD are supported by NIH grant AG05131. The authors thank the brain bank GIE NeuroCBB, the French program "Investissements d’avenir" (ANR-10-IAIHU-06). P.TJ and LM are supported by the Helsinki University Central Hospital, the Sigrid Juselius Foundation, the Foothalls Research Foundation and the Finnish Academy. HZ is a Wallenberg Academy Fellow and is supported by the Swedish Research Council. Regarding the brain samples and/or bio samples that were obtained from the MRC London Neurodegenerative Diseases Brain Bank and the Brains for Dementia Research project (funded by Alzheimer’s Society and ARUK). This research was supported in part by both the NIHR UCLH Biomedical Research Centre and the Queen Square Dementia Biomedical Research Unit. This work was supported in part by the Intramural Research Program of the National Institute on Aging, National Institutes of Health, Department of Health and Human Services; project AG000951-12. The University of Pennsylvania case collection is funded by the Penn Alzheimer’s Disease Core Center (AG10124) and the Penn Morris K. Udall Parkinson’s Disease Research Center (NS053488). The authors would like to thank the Genome Aggregation Database and the groups that provided exome and genome variant data for comparison. A full list of contributing groups can be found at https://gnomad.broadinstitute.org/. Tissue samples from UCSD are supported by NIH grant AG05131. The authors thank the brain bank GIE NeuroCBB, the French program "Investissements d’avenir" (ANR-10-IAIHU-06). P.TJ and LM are supported by the Helsinki University Central Hospital, the Sigrid Juselius Foundation, the Foothalls Research Foundation and the Finnish Academy. HZ is a Wallenberg Academy Fellow and is supported by the Swedish Research Council. Regarding the brain samples and/or bio samples that were obtained from the MRC London Neurodegenerative Diseases Brain Bank and the Brains for Dementia Research project (funded by Alzheimer’s Society and ARUK). This research was supported in part by both the NIHR UCLH Biomedical Research Centre and the Queen Square Dementia Biomedical Research Unit. This work was supported in part by the Intramural Research Program of the National Institute on Aging, National Institutes of Health, Department of Health and Human Services; project AG000951-12. The University of Pennsylvania case collection is funded by the Penn Alzheimer’s Disease Core Center (AG10124) and the Penn Morris K. Udall Parkinson’s Disease Research Center (NS053488). The authors would like to thank the Genome Aggregation Database and the groups that provided exome and genome variant data for comparison. A full list of contributing groups can be found at https://gnomad.broadinstitute.org/. Tissue samples from UCSD are supported by NIH grant AG05131. The authors thank the brain bank GIE NeuroCBB, the French program "Investissements d’avenir" (ANR-10-IAIHU-06). P.TJ and LM are supported by the Helsinki University Central Hospital, the Sigrid Juselius Foundation, the Foothalls Research Foundation and the Finnish Academy. HZ is a Wallenberg Academy Fellow and is supported by the Swedish Research Council. Regarding the brain samples and/or bio samples that were obtained from the MRC London Neurodegenerative Diseases Brain Bank and the Brains for Dementia Research project (funded by Alzheimer’s Society and ARUK). This research was supported in part by both the NIHR UCLH Biomedical Research Centre and the Queen Square Dementia Biomedical Research Unit. This work was supported in part by the Intramural Research Program of the National Institute on Aging, National Institutes of Health, Department of Health and Human Services; project AG000951-12. The University of Pennsylvania case collection is funded by the Penn Alzheimer’s Disease Core Center (AG10124) and the Penn Morris K. Udall Parkinson’s Disease Research Center (NS053488). The authors would like to thank the Genome Aggregation Database and the groups that provided exome and genome variant data for comparison. A full list of contributing groups can be found at https://gnomad.broadinstitute.org/. Tissue samples from UCSD are supported by NIH grant AG05131. The authors thank the brain bank GIE NeuroCBB, the French program "Investissements d’avenir" (ANR-10-IAIHU-06). P.TJ and LM are supported by the Helsinki University Central Hospital, the Sigrid Juselius Foundation, the Foothalls Research Foundation and the Finnish Academy. HZ is a Wallenberg Academy Fellow and is...
Authors' contributions
JB and AS conceived the study. JB, AS, RG and TO contributed to study design. JB, DH, CKR and AS contributed to data generation. JB and TO contributed to data analysis. JB, RG and TO contributed to data interpretation. TO drafted the manuscript and JB and RG performed critical review and additional writing. All other authors contributed samples. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Author details
1UK Dementia Research Institute at UCL and Department of Molecular Neuroscience, Institute of Neurology, University College London, London, UK. 2Laboratory of Neurogenetics, National Institutes on Aging, NIH, Bethesda, MD, USA. 3Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA. 4Center for Neurodegenerative Science, Van Andel Research Institute, Grand Rapids, Michigan, USA. 5Neuroscience Research Australia, Sydney, Australia, and School of Medical Sciences, Faculty of Medicine, University of New South Wales, Sydney, Australia. 6Nuffield Department of Clinical Neurosciences, Oxford Parkinson's Disease Centre, University of Oxford, Oxford, UK. 7Taub Institute for Alzheimer Disease and the Aging Brain and Department of Pathology and Cell Biology and Neurology, Columbia University Medical Center, New York, NY, USA. 8Department of Neurology and Alzheimer Center, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, the Netherlands. 9Department of Medicine, Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada. 10Clinical Memory Research Unit, Institution of Clinical Sciences Malmö, Lund University, Lund, Sweden. 11UK Dementia Research Institute at UCL and Department of Molecular Neuroscience, Institute of Neurology, University College London, London, UK. 12Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden. 13Human Genetics, School of Life Sciences, University of Nottingham, Nottingham, UK. 14Department of Basic and Clinical Neuroscience and Institute of Psychiatry, Psychology and Neurology, King's College London, London, UK. 15Queens Square Brain Bank, Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK. 16Parkinson’s Disease & Movement Disorders Unit, Neurology Service, Clinical Neuroscience Institute (CNI), Hospital Clinic, Institut de Neuropiècies, Universitat de Barcelona, IDIBAPS, Barcelona, Catalonia, Spain. 17Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research, Perelman School of Medicine at the University of Pennsylvania, 3600 Spruce Street, Philadelphia, USA. 18Banner Sun Health Research Institute, 10515 W Santa Fe Drive, Sun City, AZ 85351, USA. 19Sorbonne Université, Université Pierre et Marie Curie-Paris 06, Inserm, Centre National de la Recherche Scientifique, and l’Institut du Cerveau et de la Moelle épineure, Paris, France. 20Assistance Publique Hôpitaux de Paris, Hôpital de la Salpêtrière, Département de Genétique et Cytogénétique, Paris, France. 21Division of Neurosciences and Laboratory of Neurogenetics, National Institute on Aging/NH, Bethesda, MD, USA. 22Neurology Service, University of Coimbra Hospital, Coimbra, Portugal. 23Memory Unit, Department of Neurology, University Hospital Mutua de Terrassa, University of Barcelona, Terrassa, Barcelona, Spain. 24Centro de Investigacion Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain. 25Translational Immunology, Research Programs Unit, Department of Neurology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland. 26Department of Pathology, University of Helsinki and HUSLAB, Helsinki University Hospital, Helsinki, Finland. 27Department of Neuropathology and Neurosurgery, Helsinki University Hospital and University of Helsinki, Helsinki, Finland. 28Neurology Department, Mayo Clinic, Rochester, MN, USA. 29Department of Psychiatry and Department of Psychology, Mayo Clinic, Jacksonville, FL, USA. 30UCL Dementia Research Institute at Cardiff and MRC Centre for Neuropsychiatric Genomics, School of Medicine, Cardiff University, Cardiff, UK. 31Department of Neurology, Mayo Clinic, Jacksonville, FL, USA. 32Department of Neurology, Washington University School of Medicine, Saint Louis, MO, USA. 33Division of Neuroscience and Experimental Psychology, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK. 34Genetics and Pharmacogenomics, Merck & Co., Inc., West Point, PA, USA.

Received: 20 November 2019 Accepted: 3 January 2020
Published online: 29 January 2020

References

Received: 20 November 2019 Accepted: 3 January 2020
Published online: 29 January 2020
with cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL). J Neurol Sci. 319:37–41


**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.